Trial · NCT07001995
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995, Phase 2, Not yet recruiting, Hunan Province Tumor Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression. Trials, record NCT07001995. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07001995
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
- NCT number
- NCT07001995
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Hunan Province Tumor Hospital
- Conditions
- Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
- Interventions
- limertinib, etoposide and carboplatin
- First posted
- 2025-06-03
- Last updated
- 2026-03-16
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Time from first subject dose to study completion, or up to 36 month | define as first dose to first documented disease progression assessed by investigator or death due to any cause |
| Secondary | Objective Response Rate (ORR) | Time from first subject dose to study completion, or up to 36 month | According to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as the proportion of subjects who have a complete response (CR) or a partial response (PR) |
| Secondary | Disease control response (DcR) | Time from first subject dose to study completion, or up to 36 month | According to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as the proportion of subjects who have a complete response (CR) , partial response (PR) or stable disease (SD) |
| Secondary | Duration of Response (DoR) | Time from first subject dose to study completion, or up to 36 month | To assess duration of response for subjects with CR or PR according to RECIST version 1.1 by investigator , defined as the time from the first documented CR or PR to disease progression or death |
| Secondary | Adverse events (AEs) | From first dose to the last dose, up to 24 month | Number of participants with adverse events (AEs) according to CTCAE 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07001995
GET https://conductscience.org/api/trials/v1/NCT07001995/registered